NCT06205836View on ClinicalTrials.gov

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Colorectal Cancer
Interventions
DRUG

Cemiplimab

Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.

DRUG

Fianlimab

Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.

Trial Locations (1)

21231

RECRUITING

Johns Hopkins SKCCC, Baltimore

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER